J. Van Elk

Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene.

R. Stricker, W. Epstein, B. Goldberg, 1994, Journal of the American Academy of Dermatology.

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.

P. Vyas, C. Takimoto, S. Kambhampati, 2019, Journal of Clinical Oncology.

Pilot study of topical dinitrochlorobenzene (DNCB) in human immunodeficiency virus infection.

J. Tappero, T. Berger, D. Kiprov, 1993, Immunology letters.